ALEX

NCT02075840 📎

Regimen

Experimental
alectinib
Control
crizotinib

Population

ALK+ advanced NSCLC 1L

Key finding

mPFS 34.8 vs 10.9 mo (updated), HR 0.43 (0.32-0.58); CNS progression HR 0.16

Source: PMID 28586279

Timeline

  • Enrollment start: 2014-08-19 📎

Guideline citations

  • NCCN NSCLC Version 5.2026 (p.112)
  • CSCO NSCLC 2025 ⚠️ OCR source